Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. More Details
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Diaceutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DXRX's share price has been volatile over the past 3 months.
7 Day Return
GB Life Sciences
1 Year Return
GB Life Sciences
Return vs Industry: DXRX exceeded the UK Life Sciences industry which returned -6.8% over the past year.
Return vs Market: DXRX exceeded the UK Market which returned -13.8% over the past year.
Price Volatility Vs. Market
How volatile is Diaceutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWe're Not Counting On Diaceutics (LON:DXRX) To Sustain Its Statutory Profitability
1 month ago | Simply Wall StHow Much Of Diaceutics PLC (LON:DXRX) Do Insiders Own?
Is Diaceutics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DXRX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DXRX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DXRX is good value based on its PE Ratio (26x) compared to the GB Life Sciences industry average (56.6x).
PE vs Market: DXRX is poor value based on its PE Ratio (26x) compared to the UK market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DXRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DXRX is good value based on its PB Ratio (2.4x) compared to the GB Life Sciences industry average (4.4x).
How is Diaceutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Diaceutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Diaceutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Diaceutics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Diaceutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DXRX has a high level of non-cash earnings.
Growing Profit Margin: DXRX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: DXRX's earnings have grown significantly by 39.6% per year over the past 5 years.
Accelerating Growth: DXRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: DXRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (19.3%).
Return on Equity
High ROE: DXRX's Return on Equity (7.8%) is considered low.
How is Diaceutics's financial position?
Financial Position Analysis
Short Term Liabilities: DXRX's short term assets (£35.8M) exceed its short term liabilities (£1.6M).
Long Term Liabilities: DXRX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DXRX's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if DXRX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: DXRX's debt is well covered by operating cash flow (893.6%).
Interest Coverage: DXRX earns more interest than it pays, so coverage of interest payments is not a concern.
What is Diaceutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DXRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DXRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DXRX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Keeling (59 yo)
Mr. Peter Keeling serves as Chief Executive Officer and Executive Director at Diaceutics PLC. Mr. Keeling was Co-founder and Chief Executive at Diagnology Limited. He has an experience as a leader, entrepr ...
|CEO & Executive Director||no data||no data||20.82% |
|CFO & Executive Director||no data||no data||3.6% |
|Chief Operating Officer||no data||no data||no data|
|Chief Technical Officer||no data||no data||no data|
|VP & General Counsel||1.33yrs||no data||no data|
|Senior Director & Deputy Head of Global Sales||0.25yr||no data||no data|
|Head of Global Marketing||0.67yr||no data||no data|
|Chief Innovation Officer & Executive Director||no data||no data||3.44% |
|Head of Strategic Alliances||0.67yr||no data||no data|
|Chief Precision Officer||1.67yrs||no data||no data|
|VP & Head of Innovation||1.08yrs||no data||no data|
|Managing Director||1.08yrs||no data||no data|
Experienced Management: DXRX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.8%.
Diaceutics PLC's company bio, employee growth, exchange listings and data sources
- Name: Diaceutics PLC
- Ticker: DXRX
- Exchange: AIM
- Founded: 2005
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£99.622m
- Shares outstanding: 84.07m
- Website: https://www.diaceutics.com
Number of Employees
- Diaceutics PLC
- Titanic Suites
- Enterprise House
- County Antrim
- BT2 8FE
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|7DC||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Mar 2019|
|DXRX||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Mar 2019|
Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic r ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/19 03:48|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.